Markets
Eli Lilly’s Valuation: Blockbuster Drug vs. Top Analyst Picks
Eli Lilly benefits from a blockbuster weight loss drug, yet The Motley Fool Stock Advisor did not include LLY in its top...
#eli lilly 3 articles
Stocks
Lilly’s Retatrutide Shows Broad Benefits in Obesity Trials
Eli Lilly's experimental obesity drug retatrutide delivered positive late-stage trial results, showing substantial weight loss and improvements in type 2 diabetes, knee...
Stocks
Eli Lilly Nears $2B-Plus Kelonia Deal for Cancer Pipeline
Eli Lilly is in advanced talks to acquire Kelonia Therapeutics for over $2 billion, aiming to expand its cancer pipeline, The Wall...